Top

European Journal of Nuclear Medicine and Molecular Imaging

Published in:

01-07-2008 | Guidelines

EANM Dosimetry Committee series on standard operational procedures for pre-therapeutic dosimetry I: blood and bone marrow dosimetry in differentiated thyroid cancer therapy

Authors: Michael Lassmann, Heribert Hänscheid, Carlo Chiesa, Cecilia Hindorf, Glenn Flux, Markus Luster

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 7/2008

Abstract

Introduction

The purpose of the EANM Dosimetry Committee Series on “Standard Operational Procedures for Pre-therapeutic Dosimetry” (SOP) is to provide advice to scientists and clinicians on how to perform pre-therapeutic and/or therapeutic patient-specific absorbed dose assessments.

Material and Methods

This particular SOP gives advice on how to tailor the therapeutic activity to be administered for systemic treatment of differentiated thyroid cancer (DTC) such that the absorbed dose to the blood does not exceed 2 Gy (a widely accepted limit for bone marrow toxicity). The methodology of blood-based dosimetry has been developed in the 1960s and refined in a series of international multi-centre trials in the framework of the introduction of new diagnostic and therapeutic tools, e.g. recombinant human thyroid-stimulating hormone in the management of DTC.

Conclusion

The intention is to guide the user through a series of measurements and calculations which the authors consider to be the best and most reproducible way at present.

Benua RS, Cicale NR, Sonenberg M, Rawson RW. Relation of radioiodine dosimetry to results and complications in treatment of metastatic thyroid cancer. Am J Roentgenol Radium Ther Nucl Med 1962;87:171–82.PubMed

Benua RS, Leeper RD. A method and rationale for treating metastatic thyroid carcinoma with the largest safe dose of I-131. Frontiers in thyroidology, vol 2. New York: Plenum Medical; 1986. p. 1317–21.

Luster M, Sherman SI, Skarulis MC, Reynolds JR, Lassmann M, Hänscheid H, et al. Comparison of radioiodine biokinetics following the administration of recombinant human thyroid stimulating hormone and after thyroid hormone withdrawal in thyroid carcinoma. Eur J Nucl Med Mol Imaging 2003;30:1371–7.PubMedCrossRef

Hänscheid H, Lassmann M, Luster M, Thomas SR, Pacini F, Ceccarelli C, et al. Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal. J Nucl Med 2006;47:648–54.PubMed

Schlumberger M, Pacini F. Thyroid tumors. 5th ed. Paris: Editions Nucléon; 2003.

Schober O, Gunter HH, Schwarzrock R, Hundeshagen H. Long-term hematologic changes caused by radioiodine treatment of thyroid cancer I. Peripheral blood changes. Strahlenther Onkol 1987;163:464–74.PubMed

Gunter HH, Schober O, Schwarzrock R, Hundeshagen H. Long-term hematologic changes caused by radioiodine treatment of thyroid cancer. II. Bone marrow changes including leukemia. Strahlenther Onkol 1987;163:475–85.PubMed

Van Nostrand D, Atkins F, Yeganeh F, Acio E, Bursaw R, Wartofsky L. Dosimetrically determined doses of radioiodine for the treatment of metastatic thyroid carcinoma. Thyroid. 2002;12:121–14.PubMedCrossRef

Kolbert KS, Pentlow KS, Pearson JR, Sheikh A, Finn RD, Humm JL, et al. Prediction of absorbed dose to normal organs in thyroid cancer patients treated with ¹³¹I by use of ¹²⁴I PET and 3-dimensional internal dosimetry software. J Nucl Med 2007;48:143–9.PubMed

10.

Sgouros G. Blood and bone marrow dosimetry in radioiodine therapy of thyroid cancer. J Nucl Med 2005;46:899–900.PubMed

11.

Tuttle RM, Leboeuf R, Robbins RJ, Qualey R, Pentlow K, Larson SM, et al. Empiric radioactive iodine dosing regimens frequently exceed maximum tolerated activity levels in elderly patients with thyroid cancer. J Nucl Med 2006;47:1587–91.PubMed

12.

Samuel AM, Rajashekharrao B, Shah DH. Pulmonary metastases in children and adolescents with well-differentiated thyroid cancer. J Nucl Med 1998;39:1531–6.PubMed

13.

Medvedec M. Thyroid stunning in vivo and in vitro. Nucl Med Commun 2005;26:731–5.PubMedCrossRef

14.

Lassmann M, Luster M, Hänscheid H, Reiners C. Impact of ¹³¹I diagnostic activities on the biokinetics of thyroid remnants. J Nucl Med 2004;4:619–25.

15.

Sgouros G, Song H, Ladenson PW, Wahl RL. Lung toxicity in radioiodine therapy of thyroid carcinoma: development of a dose-rate method and dosimetric implications of the 80-mCi rule. J Nucl Med 2006;47:1977–84.PubMed

16.

Song H, Prideaux A, Du Y, Frey E, Kasecamp W, Ladenson PW, et al. Lung dosimetry for radioiodine treatment planning in the case of diffuse lung metastases. J Nucl Med 2006;47:1985–94.PubMed

17.

International Commission on Radiological Protection. ICRP publication 53: Radiation dose to patients from radiopharmaceuticals. Annals of the ICRP, vol 18. Oxford: Pergamon; 1994.

18.

Chittenden SJ, Pratt BE, Pomeroy K, Black P, Long C, Smith N, et al. Optimization of equipment and methodology for whole body activity retention measurements in children undergoing targeted radionuclide therapy. Cancer Biother Radiopharm 2007;22:243–9.PubMedCrossRef

19.

Akabani G, Poston JW Sr. Absorbed dose calculations to blood and blood vessels for internally deposited radionuclides. J Nucl Med 1991;32:830–4.PubMed

20.

Loevinger R, Holt JG, Hine JG. Internally administered radioisotopes. In: Hine JG, Brownell GL, editors. Radiation dosimetry. New York: Academic; 1956. p. 803–75.

21.

Stabin MG, Sparks RB, Crowe E. OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med 2005;46:1023–7.PubMed

22.

Leeper RD. The effect of ¹³¹I therapy on survival of patients with metastatic papillary or follicular thyroid carcinoma. J Clin Endocrinol Metab 1973;36:1143–52.PubMedCrossRef

23.

Sgouros G. Bone marrow dosimetry for radioimmunotherapy: theoretical considerations. J Nucl Med 1993;34:689–94.PubMed

24.

Chiesa C, De Agostini A, Ferrari M, Pedroli G, Savi A, Traino AC, et al. Dosimetria nella terapia medico nucleare del carcinoma tiroideo metastatico differenziato: calcolo della dose al midollo emopoietico. Notiziario Associazione Italiana Fisica in Medicina 2006;4:299–307.

25.

Traino AC, Ferrari M, Cremonesi M, Stabin MG. Influence of total-body mass on the scaling of S-factors for patient-specific, blood-based red-marrow dosimetry. Phys Med Biol 2007;52:5231–48.PubMedCrossRef

Title: EANM Dosimetry Committee series on standard operational procedures for pre-therapeutic dosimetry I: blood and bone marrow dosimetry in differentiated thyroid cancer therapy
Authors: Michael Lassmann
Heribert Hänscheid
Carlo Chiesa
Cecilia Hindorf
Glenn Flux
Markus Luster
Publication date: 01-07-2008
Publisher: Springer-Verlag
Published in: European Journal of Nuclear Medicine and Molecular Imaging / Issue 7/2008
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-008-0761-x

Keynote webinar | Spotlight on medication adherence

Springer Medicine

EANM Dosimetry Committee series on standard operational procedures for pre-therapeutic dosimetry I: blood and bone marrow dosimetry in differentiated thyroid cancer therapy

Abstract

Introduction

Material and Methods

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Introduction

Material and Methods

Conclusion

Please log in to get access to this content

Other articles of this Issue 7/2008

18F-FDG PET for the lymph node staging of non-small cell lung cancer in a tuberculosis-endemic country: Is dual time point imaging worth the effort?

The cost effectiveness of 123I-FP-CIT SPECT imaging in patients with an uncertain clinical diagnosis of parkinsonism

18F-FDG PET/CT imaging in tendon xanthomatosis

Diffuse bone marrow uptake of 99mTc (III) DMSA in Fanconi’s anemia

188Re-labelled gemcitabine/bisphosphonate (Gem/BP): a multi-functional, bone-specific agent as a potential treatment for bone metastases

Could 99mTc-glucarate be used to evaluate tumour necrosis?